Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
8-K
Other Events
2 Apr 24
S-8
Registration of securities for employees
5 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
8-K
Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
28 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Other Events
31 Jan 24
424B7
Prospectus with selling stockholder info
31 Jan 24
D
$50.00 mm in equity / options / securities to be acquired, sold $50.00 mm, 10 investors
24 Jan 24
8-K
Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023
9 Jan 24
8-K
Departure of Directors or Certain Officers
14 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Establishment Labs Reports Third Quarter 2023 Financial Results
7 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Establishment Labs Reports Record Second Quarter 2023 Financial Results
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
31 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Establishment Labs Reports Record First Quarter 2023 Financial Results
8 May 23
8-K
Entry into a Material Definitive Agreement
27 Apr 23
424B5
Prospectus supplement for primary offering
26 Apr 23
424B5
Prospectus supplement for primary offering
24 Apr 23
S-3ASR
Automatic shelf registration
24 Apr 23
8-K
Establishment Labs Announces Preliminary Unaudited Results for First Quarter 2023
24 Apr 23
8-K
Establishment Labs Notes Presentation of 3-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2023
20 Apr 23
ARS
2022 FY
Annual report to shareholders
12 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
PRE 14A
Preliminary proxy
28 Mar 23
S-8
Registration of securities for employees
1 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Results of Operations and Financial Condition
27 Feb 23
8-K
Founder & CEO Establishment Labs JUAN JOSÉ CHACÓN-QUIRÓS JANUARY 12th, 2023 41 Annual J.P. Morgan Healthcare Conference st
11 Jan 23
8-K
Establishment Labs Announces Preliminary Unaudited Revenue for Fourth Quarter and Fiscal Year 2022
9 Jan 23
8-K
Departure of Directors or Certain Officers
2 Dec 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Establishment Labs Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Departure of Directors or Certain Officers
2 Sep 22
Latest ownership filings
4
Raj Denhoy
11 Apr 24
4/A
Samuel Ross Mansbach
5 Apr 24
4
Leslie Gillin
2 Apr 24
4
EDWARD J SCHUTTER
2 Apr 24
4
DENNIS E CONDON
2 Apr 24
4
NICHOLAS SHERIDAN LEWIN
2 Apr 24
4
Bryan Slotkin
2 Apr 24
4
Ann Custin
2 Apr 24
4
Samuel Ross Mansbach
19 Mar 24
4
Raj Denhoy
19 Mar 24
4
Quiros Juan Jose Chacon
19 Mar 24
4
Samuel Ross Mansbach
7 Mar 24
4
Raj Denhoy
7 Mar 24
4
EDWARD J SCHUTTER
5 Mar 24
4
Bryan Slotkin
5 Mar 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G
Chacon Quiros Juan Jose
9 Feb 24
SC 13G/A
BROWN ADVISORY INC
9 Feb 24
4
Leslie Gillin
8 Jan 24
4
DENNIS E CONDON
8 Jan 24
4
Ann Custin
8 Jan 24
4
NICHOLAS SHERIDAN LEWIN
4 Jan 24
4
Bryan Slotkin
3 Jan 24
4
EDWARD J SCHUTTER
3 Jan 24
4
NICHOLAS SHERIDAN LEWIN
15 Dec 23
4
NICHOLAS SHERIDAN LEWIN
21 Nov 23
4
Raj Denhoy
20 Nov 23
4
NICHOLAS SHERIDAN LEWIN
15 Nov 23
4
EDWARD J SCHUTTER
3 Oct 23
4
Bryan Slotkin
3 Oct 23
4
NICHOLAS SHERIDAN LEWIN
16 Aug 23
4
EDWARD J SCHUTTER
5 Jul 23
4
Bryan Slotkin
5 Jul 23
4
NICHOLAS SHERIDAN LEWIN
31 May 23
4
Bryan Slotkin
26 May 23
4
DENNIS E CONDON
26 May 23
4
EDWARD J SCHUTTER
26 May 23
4
Ann Custin
26 May 23
4
NICHOLAS SHERIDAN LEWIN
26 May 23